Gemfibrozil (Pharmacor)

What it is used for

PHARMACOR GEMFIBROZIL 600 is indicated as an adjunct to diet and other therapeutic measures for: Severe hypertriglyceridaemia (Type IV and V) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Dyslipidaemia associated with diabetes. Reduction of risk of coronary heart disease in patients with Type IIa and IIb hypercholesterolaemia. Because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemibrozil in treating Type IIa patients with elevations of LDL-cholesterol only is not likely to outweigh the risks. In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL-cholesterol values at baseline (greater than 1.2mmol/L), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. NOTE: PHARMACOR GEMFIBROZIL 600 IS INDICATED WHEN EXERCISE, WEIGHT LOSS AND SPECIFIC DIETARY OR OTHER NON-DRUG MEASURES SUCH AS LIMITING ALCOHOL INTAKE HAVE FAILED. OTHER MEDICAL DISORDERS SUCH AS HYPOTHYROIDISM AND DIABETES SHOULD BE CONTROLLED AS MUCH AS POSSIBLE. PERIODIC DETERMINATION OF SERUM LIPIDS SHOULD BE OBTAINED DURING TREATMENT WITH PHARMACOR GEMFIBROZIL 600. THE DRUG SHOULD BE WITHDRAWN OR ADDITIONAL THERAPY INSTITUTED IF THE LIPID RESPONSE IS DEEMED INADEQUATE AFTER THREE MONTHS.,PHARMACOR GEMFIBROZIL 600 is indicated as an adjunct to diet and other therapeutic measures for: Severe hypertriglyceridaemia (Type IV and V) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Dyslipidaemia associated with diabetes. Reduction of risk of coronary heart disease in patients with Type IIa and IIb hypercholesterolaemia. Because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating Type IIa patients with elevations of LDL-cholesterol only is not likely to outweigh the risks. In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL-cholesterol values at baseline (greater than 1.2mmol/L), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. NOTE: PHARMACOR GEMFIBROZIL 600 IS INDICATED WHEN EXERCISE, WEIGHT LOSS AND SPECIFIC DIETARY OR OTHER NON-DRUG MEASURES SUCH AS LIMITING ALCOHOL INTAKE HAVE FAILED. OTHER MEDICAL DISORDERS SUCH AS HYPOTHYROIDISM AND DIABETES SHOULD BE CONTROLLED AS MUCH AS POSSIBLE. PERIODIC DETERMINATION OF SERUM LIPIDS SHOULD BE OBTAINED DURING TREATMENT WITH PHARMACOR GEMFIBROZIL 600. THE DRUG SHOULD BE WITHDRAWN OR ADDITIONAL THERAPY INSTITUTED IF THE LIPID RESPONSE IS DEEMED INADEQUATE AFTER THREE MONTHS.